Ipsen CBO: We Are Seeking Fresh Rare Disease Buys
“Externalization” Needed To Re-Fill Its Maturing Pipeline
Executive Summary
Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.